Methodology: 175 T2DM patients on regular follow-up with microalbuminuria (eUACR >30), aged <75 years, irrespective of their A1c, on standard glucose, lipid and blood pressure lowering therapy using ARB (valsartan or telmisartan) were followed-up for 2 years. 2 groups were identified, Control group (Cn) on conventional dose CDARB’s and case (Cs) group on high dose HDARB’s. Renal (creatinine, eGFR, UACR) and CV (SBP, DBP, BMI, Lipid profile, hs-CRP) parameters were evaluated in both groups at 3-6 monthly intervals. NT-ProBNP was evaluated in both groups at the end of the study. Patients with history of any revascularization, IHD or hospitalization in last 1 year, eGFR <45, hyperkalemia >5.5 were excluded. Data was analysed using PSPP version 1.0.1 and represented as Mean (Standard deviation), independent sample t-test and paired t test was used. P-value of 0.05 was considered significant.

Results: Both groups Cs and Cn were well matched for treatment and clinical characteristics except DBP, higher mean in Cs (81 ±11.39) vs. Cn (76.80 ± 11.58, p 0.025). Mean CDARB dose in Cn group (Telmisartan 55.15mg (SD ± 24) and valsartan 115.76 (SD ±47.82) vs. Cs group HDARB (telmisartan 222.22mg (SD±49.22) and valsartan 334.58 (SD±77.81). Within the cases there was a significant reduction seen in A1c, SBP, hs-CRP, lipid parameters and UACR over 2 years. Within the control group there was a significant reduction seen in A1c, lipid parameters, UACR. At the end of the follow-up there was significant reduction seen in Cs in LDL (Cs 51.34 ±19.73 vs. Cn 63.82 ± 25.97, p-0.005) and non-HDL (Cs 66.77 ±34.74 vs. Cn 51.70 ±44.56, p-0.023). There was a trend towards reduction in hs-CRP in Cs (Cs 1.74 ± 1.92 vs. Cn 2.53 ± 3.70, p-0.066). The NT-ProBNP remained high in both groups (142.86 ±232.32 vs. 192.61 ±260.93, p-0.203).

Conclusion: HDARB may be associated with better vascular protection as shown by improvements in LDL, non-HDL and hs-CRP compared to CDARB in T2DM with microalbuminuria.


V. Gupta: None. V. Teli: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at